Shi L, Xie Y, Liu J, Kissinger P, Khan M
Department of Global Health Systems and Development, School of Public Health and Tropical Medicine,Tulane University, New Orleans, LA, USA.
Int J STD AIDS. 2013 Apr;24(4):301-6. doi: 10.1177/0956462412472821. Epub 2013 Jun 14.
We aimed to examine whether out-of-pocket (OOP) costs associated with chlamydia (CT) and gonorrhoea (GC) screening tests is a barrier to receiving CT/GC re-screening and follow-up annual screening. A major health insurance claims database 2006-2010 was used for analysis. The date of first CT/GC diagnosis was used as the index date, and OOP costs at index date for screening tests were retrieved. A re-screening test and an annual screening were defined as tests that occurred within 90-180 days and 181-395 days of the index date, respectively. Re-screening rates were 11.7% and 10.9% and annual screening rates were 24.7% and 23.7% for CT and GC cases, respectively. Compared with the CT patients without OOP expenses, those with OOP expenses of $30 or higher had significantly reduced likelihood of receiving re-screening and annual screening. Similar results were found for GC patients. We concluded that OOP costs serve as a significant barrier to re-screening and annual screening.
我们旨在研究与衣原体(CT)和淋病(GC)筛查检测相关的自付费用是否会成为接受CT/GC复查及后续年度筛查的障碍。分析使用了一个2006年至2010年的大型医疗保险理赔数据库。首次CT/GC诊断日期被用作索引日期,并获取索引日期时筛查检测的自付费用。复查检测和年度筛查分别定义为在索引日期的90至180天内和181至395天内进行的检测。CT和GC病例的复查率分别为11.7%和10.9%,年度筛查率分别为24.7%和23.7%。与没有自付费用的CT患者相比,自付费用达到或超过30美元的患者接受复查和年度筛查的可能性显著降低。GC患者也有类似结果。我们得出结论,自付费用是复查和年度筛查的重大障碍。